News: Immuron starts sponsored Phase 2 trial for treatment of alcoholic steatohepatitis

Immuron Limited (ASX:IMC) has started the fully sponsored Phase 2 clinical trial in the U.S. for the treatment of alcoholic steatohepatitis (ASH) using its IMM-124E treatment.

IMM-124E is one of three therapeutic candidates selected by the United States National Institutes of Health (NIH) from 27 therapeutic candidates to be trailed for the treatment of ASH.

The trial is sponsored and funded by the US NIH and is expected to provide data that will complement Immuron’s non-alcoholic steatohepatitis (NASH) clinical development program

IMM-124E is a natural product for the treatment of fatty liver associated with ASH and NASH. IMM-124E contains the natural ingredient Bovine Colostrum Powder that is harvested from dairy cows which are immunised with Immuron’s proprietary vaccine.

By vaccinating the cows, Immuron causes a shift in the bovine colostrum antibody composition, which is designed to confer on IMM-124E its pharmaceutical quality.

Recruitment is already underway for the ASH trial with the first three of a planned 66 patients already enrolled.

ASH has a poor prognosis and is a syndrome of progressive inflammatory liver injury associated with long-term heavy alcohol consumption. There is no approved drug for the treatment of this disease.